Biomarkers /
ARID5B
Overview
ARID5B is altered in 1.51% of all cancers with breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, conventional glioblastoma multiforme, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in ARID5B are ARID5B Loss (0.36%), ARID5B Amplification (0.30%), ARID5B I497* (0.06%), ARID5B E456* (0.02%), and ARID5B E454* (0.01%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.